Zepbound vs Mounjaro: Switching Between Them

What Are Zepbound and Mounjaro, Really?

Zepbound and Mounjaro are the same drug in different packaging. Both deliver tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist approved by the FDA. Tirzepatide activates two incretin pathways simultaneously, a mechanism distinct from semaglutide, which targets GLP-1 alone. The pen devices, excipients, dose strengths, and injection schedule are identical across both branded products. The FDA approved Mounjaro for type 2 diabetes in May 2022 and Zepbound for chronic weight management in November 2023.

Why Two Brand Names for One Molecule?

Eli Lilly pursued two separate regulatory pathways because FDA approval requires indication-specific clinical programs. SURPASS-2 (N=1,879) demonstrated tirzepatide's glycemic efficacy in type 2 diabetes, supporting the Mounjaro application. SURMOUNT-1 (N=2,539) demonstrated weight loss in adults without diabetes, forming the basis for Zepbound's approval. A single molecule can carry two brand names when a manufacturer funds separate Phase 3 programs targeting distinct indications.

Mechanism: GIP Plus GLP-1

GIP receptors are expressed in adipose tissue, the central nervous system, and pancreatic beta cells. GLP-1 receptors mediate appetite suppression and incretin-stimulated insulin release. Tirzepatide's simultaneous action on both receptor types likely explains why its weight-loss numbers exceed those seen with GLP-1-only agents in head-to-head comparisons. SURPASS-2 showed tirzepatide 15 mg reduced A1C by 2.3 percentage points compared with 1.86 percentage points for semaglutide 1 mg (P<0.001), and produced 12.4% mean body-weight loss versus 6.2% for semaglutide 1 mg at 40 weeks.

Clinical Evidence Behind Each Approval

SURMOUNT-1: The Weight-Loss Case

SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with a BMI of 30 or higher (or 27 or higher with at least one weight-related comorbidity) and without type 2 diabetes. Participants were randomized to tirzepatide 5 mg, 10 mg, or 15 mg or placebo once weekly for 72 weeks. Mean weight loss at 72 weeks reached 15.0% for the 5 mg group, 19.5% for 10 mg, and 20.9% for 15 mg, compared with 3.1% for placebo. Roughly 37% of participants in the 15 mg arm achieved at least 25% total body-weight loss.

Those results directly underpin the Zepbound label. Prescribers writing for weight management use SURMOUNT-1 data when counseling patients on expected outcomes.

SURPASS-2: The Diabetes Case

SURPASS-2 (N=1,879), published in NEJM in 2021, compared tirzepatide 5 mg, 10 mg, and 15 mg with semaglutide 1 mg subcutaneous in adults with type 2 diabetes on metformin. At 40 weeks, tirzepatide 15 mg reduced A1C by a mean of 2.3 percentage points versus 1.86 percentage points for semaglutide 1 mg, a statistically significant difference. Body weight fell by 12.4% in the tirzepatide 15 mg arm versus 6.2% in the semaglutide 1 mg arm.

The SURPASS-2 data gave Lilly the clinical foundation for Mounjaro's type 2 diabetes label and positioned tirzepatide as the highest-efficacy approved agent in its class at the time of filing.

What the Trials Do Not Tell Us

No published head-to-head trial compares Zepbound to Mounjaro, because no such trial could exist. They are the same molecule. Any claim that one brand outperforms the other at identical doses is not supported by clinical data. Differences in individual response reflect patient biology, diet, adherence, and titration speed rather than brand.

Dose Equivalence and Titration

Both pens are available in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The standard titration schedule for both starts at 2.5 mg once weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated up to a maximum of 15 mg once weekly. The FDA-approved prescribing information for Mounjaro and the Zepbound label both specify this identical schedule.

Switching Without a Dose Gap

When a patient switches between Zepbound and Mounjaro, no dose adjustment is required. A patient stabilized on Mounjaro 10 mg once weekly continues at tirzepatide 10 mg once weekly under the Zepbound label. The injection is given on the same weekday, at the same site, using the same autoinjector technique. There is no washout period, no re-titration from 2.5 mg, and no bridging protocol needed.

When Re-Titration May Be Considered

Re-titration from a lower dose is sometimes considered if a patient had a prolonged gap in therapy, typically more than 4 weeks off the drug entirely. That decision applies regardless of which brand name resumes treatment. According to the American Association of Clinical Endocrinology (AACE) obesity management algorithm, shared decision-making on titration speed should account for tolerability history, not brand identity.

Why Patients Switch: Real-World Drivers

Insurance Coverage and Prior Authorization

The single most common reason a patient changes between Zepbound and Mounjaro is insurance coverage. Many commercial plans cover Mounjaro for type 2 diabetes under pharmacy benefits but exclude Zepbound for obesity, because obesity coverage remains inconsistently covered under commercial and government payers. A 2023 analysis published through NCBI found that coverage of anti-obesity medications varied substantially across employer-sponsored plans, with fewer than 30% of large employers offering comprehensive GLP-1 obesity coverage as of that year.

Conversely, some patients with type 2 diabetes have better Zepbound cost-sharing through manufacturer savings programs or state-specific Medicaid expansions. The prescriber needs to verify the active diagnosis on the prior authorization form, not simply the brand.

Cost Without Insurance

As of 2024 published wholesale acquisition costs, Mounjaro lists at approximately $1,069 per 4-pen carton and Zepbound at approximately $1,059 per 4-pen carton. The difference is negligible for cash-pay patients. Both brands offer manufacturer savings cards that reduce out-of-pocket costs significantly for eligible commercially insured patients, though neither card applies to Medicare or Medicaid beneficiaries. The FDA Approved Drug Products database lists both products under tirzepatide with separate application numbers.

Compounded Tirzepatide and the Formulary Gap

During 2023 and early 2024, FDA-declared shortage status for tirzepatide allowed 503B outsourcing facilities to compound tirzepatide. The FDA removed tirzepatide from the drug shortage list in December 2024, effectively ending the legal basis for compounded versions. Patients previously using compounded tirzepatide now transitioning to branded Zepbound or Mounjaro should confirm dose equivalence carefully, as compounded preparations were sometimes dispensed in multi-dose vials at concentrations differing from the autoinjector.

Is Zepbound Better Than Mounjaro?

Neither brand is pharmacologically superior. At the same dose, on the same schedule, in the same patient, they produce identical plasma tirzepatide concentrations. The question of "better" reduces entirely to insurance coverage, formulary status, and manufacturer rebates in a given patient's specific plan.

The HealthRX clinical team uses a three-question decision framework when a patient asks which brand to request:

1. What diagnosis is being treated? Obesity or overweight with a weight-related comorbidity supports a Zepbound prior authorization. Type 2 diabetes supports a Mounjaro prior authorization. Some patients qualify for both.
2. Which brand does the plan cover, and at what tier? Run a real-time eligibility check before writing the prescription. Coverage can differ by plan year, employer group, and state.
3. Is the patient Medicare-eligible? Medicare Part D covers Mounjaro for type 2 diabetes but, under current law, does not cover Zepbound for obesity unless a concurrent diabetes diagnosis applies. The Centers for Medicare and Medicaid Services (CMS) guidance on anti-obesity medications has been evolving, and the prescriber should verify current Part D formulary status at the time of prescribing.

If both brands have equivalent coverage, prescribe whichever the pharmacy has in stock. There is no clinical basis for preference.

Safety Profile: Shared Across Both Labels

Because the active ingredient is identical, the safety data from SURMOUNT-1 and SURPASS-2 apply to both products without distinction. The most common adverse events are gastrointestinal: nausea (reported by approximately 25-30% of participants at the 15 mg dose in SURMOUNT-1), diarrhea, vomiting, and constipation. These events occur most often during dose escalation and generally diminish after 4 to 8 weeks at a stable dose.

Serious Risks on Both Labels

Both Zepbound and Mounjaro carry a boxed warning for thyroid C-cell tumors based on rodent data. The FDA label for both products contraindicates tirzepatide in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pancreatitis, acute gallbladder disease, hypoglycemia (particularly in patients on sulfonylureas or insulin), and acute kidney injury from dehydration are listed risks common to both labels.

Cardiovascular Outcomes Data

The SURMOUNT-MMO cardiovascular outcomes trial for tirzepatide in obesity was ongoing as of early 2025. Cardiovascular benefit data specific to the weight-management indication in non-diabetic patients were not yet published at the time this article was reviewed. For patients with type 2 diabetes, a 2023 meta-analysis on GLP-1 receptor agonist cardiovascular outcomes (PMID 37490136) noted class-level cardiovascular benefits, though tirzepatide-specific CVOT data in the diabetes population remain under evaluation in the SURPASS-CVOT trial.

Practical Switching Protocol

Step 1: Verify the Indication and Diagnosis Code

The prescriber must confirm the ICD-10 code being submitted. E11.x (type 2 diabetes mellitus) supports Mounjaro. E66.x (obesity) or Z68.x (BMI codes) supports Zepbound. Submitting the wrong code for the wrong brand is the most common prior authorization error in switching scenarios.

Step 2: Confirm Current Dose

Document the patient's current tirzepatide dose in milligrams per week. A patient on Mounjaro 7.5 mg once weekly transitions directly to Zepbound 7.5 mg once weekly. Do not restart at 2.5 mg unless the patient has been off the drug for more than 4 consecutive weeks.

Step 3: Timing of the Switch

The switch can happen on any injection day. The patient takes their last Mounjaro injection on a given day and then takes their first Zepbound injection exactly 7 days later. No overlap, no gap.

Step 4: Monitor for Formulary or Supply Issues

At the pharmacy level, Zepbound and Mounjaro are dispensed as separate National Drug Codes (NDCs). A pharmacist cannot substitute one for the other without a new prescription, even though the active ingredient is identical, because the FDA has not designated them as therapeutic equivalents in the Orange Book. The prescriber must write a new script for the new brand.

Populations That May Need Additional Guidance

Patients with both type 2 diabetes and obesity (a common combination) may qualify for either brand. The American Diabetes Association Standards of Care 2024 recommends selecting anti-obesity medications with cardiovascular and renal benefit data when managing patients with T2D and elevated BMI, and tirzepatide appears on those recommendation lists under both indications. For these patients, the prescriber should select the brand that yields the lowest net patient cost, because the clinical outcome will be identical.

Patients with obesity and prediabetes but not yet diagnosed with T2D do not meet the Mounjaro indication. Attempting to prescribe Mounjaro for prediabetes off-label may trigger a prior authorization denial. Zepbound's label covers BMI <30 with a qualifying comorbidity, and prediabetes is listed as a qualifying condition on the Zepbound label.

Frequently Asked Questions